Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical India Legal Issues

Insider Analysis From Corporate Law Group New Delhi On India’s Drug Pricing Regulations

This article was originally published in PharmAsia News

Executive Summary

A new pricing proposal under consideration could extend price controls to 75% of the Indian retail market.

You may also be interested in...



With Over 348 Drugs In Proposed Pricing Policy, India Aims To Balance Industry Growth With Affordable Drugs

MUMBAI - After lying in hibernation for several years, policy proposals for tighter government control on pricing of the most used medicines in India is back in the headlines as the Department of Pharmaceuticals last week posted a comprehensive draft pricing policy and called for feedback from stakeholders before Nov. 30

Table

View full table

Topics

Tags:
BioPharmaceutical India Legal Issues
Latest Headlines

Lilly Can Rest Easy As Tirzepatide Scores Phase III Sleep Apnea Win

Sage’s Dalzanemdor Prospects In Doubt After First Mid-Stage Readout

Teva Says The Time Is Right For Two Big Immunology Biosimilar Launches

Precision Keeps Faith In Duchenne Gene-Editing After Lilly’s Exit

See All
UsernamePublicRestriction

Register

SC080886

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By